Celiac Disease Diagnostics Market- Growth, Share, Opportunities & Competitive Analysis, 2024 – 2032

Market Overview
The Celiac Disease Diagnostics Market is projected to grow from USD 307.3 million in 2024 to USD 568.79 million by 2032, at a robust compound annual growth rate (CAGR) of 8% during the forecast period.

The market is driven by the rising global prevalence of celiac disease, coupled with increasing awareness of the condition and its complications. Significant advancements in diagnostic technologies, such as serological tests and genetic screening, have enabled earlier detection and improved disease management. The adoption of non-invasive diagnostic methods and the growing focus on personalized medicine further boost market growth. Additionally, supportive government initiatives aimed at promoting early diagnosis and treatment of autoimmune disorders have increased demand for diagnostic solutions. The development of advanced point-of-care testing devices, offering faster and more convenient detection, is a key trend. The integration of artificial intelligence (AI) and machine learning (ML) into diagnostic tools has also enhanced their accuracy and predictive capabilities, further contributing to the market’s growth.

Market Drivers

Advancements in Diagnostic Technologies
Technological innovations have significantly improved the accuracy and efficiency of celiac disease detection. For example, Quest Diagnostics has introduced next-generation serological tests that reduce diagnostic time and improve patient outcomes. These innovations, including next-generation serological tests, genetic screening, and point-of-care testing devices, enable healthcare professionals to diagnose celiac disease more effectively and quickly, driving market growth.

Market Challenges Analysis

Limited Awareness and Underdiagnosis
Despite increased awareness, a major challenge facing the Celiac Disease Diagnostics Market is the continued underdiagnosis of the condition. Many individuals remain undiagnosed due to a lack of awareness about the disease’s symptoms and potential severity. This issue is particularly pronounced in emerging economies where awareness campaigns and educational initiatives may be insufficient. Misdiagnosis is also common due to the overlap in symptoms with other gastrointestinal disorders, leading to delayed intervention and increasing the risk of long-term complications. These factors limit the growth potential of the market, highlighting the need for broader educational initiatives, improved healthcare provider training, and better diagnostic protocols to address these critical gaps.

Segmentation

By Treatment

Vitamins & Minerals

Gluten-Free Diet

Medical Therapies

Infliximab

Larazotide Acetate

Azathioprine

Budesonide

Others

By Route of Administration

Oral

Parenteral

By Distribution Channel

Hospitals

Research Centers

Others

By Region

North America

U.S.

Canada

Mexico

Europe

Germany

France

U.K.

Italy

Spain

Rest of Europe

Asia Pacific

China

Japan

India

South Korea

South-East Asia

Rest of Asia Pacific

Latin America

Brazil

Argentina

Rest of Latin America

Middle East & Africa

GCC Countries

South Africa

Rest of the Middle East and Africa

Key Player Analysis

Amneal Pharmaceuticals LLC

Takeda Pharmaceutical Company Limited

Zydus Pharmaceuticals, Inc.

Amgen Inc.

Hikma Pharmaceuticals PLC

BioLineRx Ltd.

Glenmark Life Sciences Limited

Viatris Inc.

Novartis AG

Teva Pharmaceutical Industries Ltd.